Melanoma - Pipeline Insight, 2025
Description
DelveInsight’s, “Melanoma- Pipeline Insight, 2025,”report provides comprehensive insights about 150+ companies and 170+ pipeline drugs in Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Melanoma: Overview
Melanoma is considered as a type of cancer that develops in the pigment-producing melanocyte cells. Anyway, tumors will grow in melanocytes of the skin in almost 90% of cases; it can also occur in melanocytes of the eye, internal organs, and mucosal membranes lining the gastrointestinal, respiratory and urogenital tracts. Melanoma is the third most common cutaneous malignancy after basal cell carcinoma and squamous cell carcinoma. Melanoma is the fifth most common malignancy in males and sixth most common malignancy in females. It is considered one of the most challenging diseases to treat with pharmacotherapy; melanoma drug development lagged than many other cancers, going on in decades with limited progress.
Common melanoma metastasis sites include the lymph nodes, lungs, liver, bones and brain. Common symptoms of melanoma includes a new, unusual growth or a change in an existing mole the person may experience bigger mole diameter, darkening of the skin, mole color changes, or skin mole with irregular border, a skin sore that fails to heal, a spot or sore that becomes painful, itchy, or tender melanomas can occur anywhere on the body. During diagnosing with melanoma, doctor will do a skin exam and also the ABCDE examination. If they think patient may have skin cancer, patient would need a biopsy to find out. Usually gets one of three types: Punch biopsy. This removes a round piece of skin. Excisional biopsy: doctor takes out the entire growth. Shave biopsy: doctor tries to shave off the entire growth. A doctor will look at the growth under a microscope to see how thick it is. Usually, a thicker tumor means there is a higher risk the cancer will spread. Additional tests are needed to determine whether the cancer is metastatic melanoma, or if there’s no visible primary tumor.
There are various methods to diagnose the melanoma that includes sentinel lymph node biopsy, CT-Scans, MRI Scan, and PET scan, blood tests may be used to measure lactate dehydrogenase (LDH) before treatment. Other tests include blood chemistry levels and blood cell counts. Melanoma treatment depends on the current stage of the melanoma and general health of the person. Treatments for this disease includes melanoma surgery in early stages, surgery has a high probability of being able to cure the melanoma. Lymphadenectomy in cases where melanoma has spread, removal of the lymph nodes near the primary diagnosis site may be required this can prevent the spread to other areas of the body. Metastasectomy is used to remove small melanoma bits from organs. Targeted cancer therapy in this treatment option, drugs are used to attack specific cancer cells. Radiation therapy is also opted by many doctors and lastly the immunotherapy which is adopted by many biopharma companies for the treatment of melanoma.
""Melanoma- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Melanoma pipeline landscape is provided which includes the disease overview and Melanoma treatment guidelines. The assessment part of the report embraces, in depth Melanoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Melanoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Melanoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Melanoma Emerging Drugs
Further product details are provided in the report……..
Melanoma: Therapeutic Assessment
This segment of the report provides insights about the different Melanoma drugs segregated based on following parameters that define the scope of the report, such as:
Melanoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III II, I, preclinical and discovery stage. It also analyses Melanoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Melanoma drugs.
Melanoma Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Melanoma: Overview
Melanoma is considered as a type of cancer that develops in the pigment-producing melanocyte cells. Anyway, tumors will grow in melanocytes of the skin in almost 90% of cases; it can also occur in melanocytes of the eye, internal organs, and mucosal membranes lining the gastrointestinal, respiratory and urogenital tracts. Melanoma is the third most common cutaneous malignancy after basal cell carcinoma and squamous cell carcinoma. Melanoma is the fifth most common malignancy in males and sixth most common malignancy in females. It is considered one of the most challenging diseases to treat with pharmacotherapy; melanoma drug development lagged than many other cancers, going on in decades with limited progress.
Common melanoma metastasis sites include the lymph nodes, lungs, liver, bones and brain. Common symptoms of melanoma includes a new, unusual growth or a change in an existing mole the person may experience bigger mole diameter, darkening of the skin, mole color changes, or skin mole with irregular border, a skin sore that fails to heal, a spot or sore that becomes painful, itchy, or tender melanomas can occur anywhere on the body. During diagnosing with melanoma, doctor will do a skin exam and also the ABCDE examination. If they think patient may have skin cancer, patient would need a biopsy to find out. Usually gets one of three types: Punch biopsy. This removes a round piece of skin. Excisional biopsy: doctor takes out the entire growth. Shave biopsy: doctor tries to shave off the entire growth. A doctor will look at the growth under a microscope to see how thick it is. Usually, a thicker tumor means there is a higher risk the cancer will spread. Additional tests are needed to determine whether the cancer is metastatic melanoma, or if there’s no visible primary tumor.
There are various methods to diagnose the melanoma that includes sentinel lymph node biopsy, CT-Scans, MRI Scan, and PET scan, blood tests may be used to measure lactate dehydrogenase (LDH) before treatment. Other tests include blood chemistry levels and blood cell counts. Melanoma treatment depends on the current stage of the melanoma and general health of the person. Treatments for this disease includes melanoma surgery in early stages, surgery has a high probability of being able to cure the melanoma. Lymphadenectomy in cases where melanoma has spread, removal of the lymph nodes near the primary diagnosis site may be required this can prevent the spread to other areas of the body. Metastasectomy is used to remove small melanoma bits from organs. Targeted cancer therapy in this treatment option, drugs are used to attack specific cancer cells. Radiation therapy is also opted by many doctors and lastly the immunotherapy which is adopted by many biopharma companies for the treatment of melanoma.
""Melanoma- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Melanoma pipeline landscape is provided which includes the disease overview and Melanoma treatment guidelines. The assessment part of the report embraces, in depth Melanoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Melanoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Melanoma R&D. The therapies under development are focused on novel approaches to treat/improve Colorectal Cancer.
This segment of the Melanoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Melanoma Emerging Drugs
- IO102 IO103 : IO Biotech
- mRNA 4157: Moderna Inc.
- MK-4830: Merck Sharp & Dohme LLC
- BNT111: BioNTech SE
- TILT 123: TILT Biotherapeutics LLC
Further product details are provided in the report……..
Melanoma: Therapeutic Assessment
This segment of the report provides insights about the different Melanoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Melanoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Melanoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III II, I, preclinical and discovery stage. It also analyses Melanoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Melanoma drugs.
Melanoma Report Insights
- Melanoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Melanoma drugs?
- How many Melanoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Melanoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Melanoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Melanoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- IO Biotech
- Moderna Inc.
- Merck Sharp & Dohme LLC
- BioNTech SE
- TILT Biotherapeutics LLC
- Nykode Therapeutics
- Achilles Therapeutics UK Limited
- Evaxion Biotech
- InxMed
- AiVita Biomedical
- Cytovation AS
- Ono Pharmaceuticals
- Neon Therapeutics
- Iovance Biotherapeutics
- IO102 IO103
- mRNA 4157
- MK-4830
- BNT111
- TILT 123
- VB10 NEO
- LN-145-S1
- NEO-PV-01
- ONO4482
- BMS- 986249
- SEA-CD40
Table of Contents
180 Pages
- Introduction
- Executive Summary
- Melanoma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
- Comparative Analysis
- IO102 IO103 : IO Biotech
- Product Description
- Research and Development
- Product Development Activities
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- MK-4830: Merck Sharp & Dohme LLC
- Product Description
- Research and Development
- Early Stage Products (Phase I)
- Comparative Analysis
- TILT 123: TILT Biotherapeutics LLC
- Product Description
- Research and Development
- Product Development Activities
- Inactive Products
- Comparative Analysis
- Melanoma Key Companies
- Melanoma Key Products
- Melanoma- Unmet Needs
- Melanoma- Market Drivers and Barriers
- Melanoma- Future Perspectives and Conclusion
- Melanoma Analyst Views
- Melanoma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
